List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
5 June 2025 | By WuXi Biologics
Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimize antibody leads in early drug discovery - and mitigate downstream risks later in development.
Researchers at the University of Illinois have achieved the first successful metabolic labelling of platelets, a key step toward using them in targeted drug delivery. The technique could enable short-lived, precision therapies for cancer, immune conditions, and clotting disorders.
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
Antibody-drug conjugates (ADCs) are transforming cancer therapy by enabling targeted drug delivery with minimised side effects, but their complex structure presents unique challenges in bioanalysis. This article explores cutting-edge strategies for optimising ADC evaluation, from quantifying drug-to-antibody ratios (DAR) to overcoming hurdles like payload interference and stability.
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
Researchers have developed a test that accurately predicts whether patients with ALK-positive lung cancer will respond to targeted treatments. This could significantly enhance personalised cancer therapies and overcome treatment resistance.
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
4 April 2025 | By Eurofins Discovery
Join Dr. Francisca Neethling from Eurofins Discovery to explore the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
21 March 2025 | By Abzena
Watch our webinar with Abzena’s experts to explore practical solutions for overcoming chemistry, manufacturing and regulatory challenges in antibody-oligonucleotide conjugate (AOC) development, enabling progress for previously untreatable diseases.
Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has partnered with Rarity Bioscience to introduce a groundbreaking approach to oncology research.
CN Bio has developed an advanced hepatotoxicity testing solution to improve preclinical drug safety, providing more human-relevant insights and reducing the risk of drug failures due to liver damage.
A new study reveals how specific immune cells contribute to the exaggerated immune response in food allergies, offering hope for improved treatments in the future.
